Browsing by Keyword : HER2
Showing results 1 to 12 of 12
- 1 Article A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas 2023
- 2 Article An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers 신설화 ; 박윤희 ; 박석순 ; et al 2021
- 3 Article Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels 2023
- 4 Article Crotamine-based recombinant immunotoxin targeting HER2 for enhanced cancer cell specificity and cytotoxicity 2023
- 5 Article Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma 김규표 ; 김성주 ; 성유나 ; et al 2021
- 6 Article Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin 김규표 ; 류백렬 ; 박도현 ; et al 2021
- 7 Article Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin 김규표 ; 류백렬 ; 박도현 ; et al 2021
- 8 Article HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer 2023
-
9
Dissertation
HER2 과발현 유방암 세포에서의 면역접합체 HER2(scFv)–PE24의 세포독성 효과
이선주
2018
- 10 Article Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen Han Kyu Chae ; Wook Nam ; Han Gwun Kim ; et al 2022
- 11 Article MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma 강윤구 ; Daniel VT Catenacci ; Harry H Yoon ; et al 2021
- 12 Article Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18 2023
1